Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global Achondroplasia Treatment Market by Type (CNP Analogue, Ligand Trap, TKI, Others), By Application (Hospital, Retail Pharmacy, Others) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global Achondroplasia Treatment Market by Type (CNP Analogue, Ligand Trap, TKI, Others), By Application (Hospital, Retail Pharmacy, Others) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 430899 4200 Chemical & Material 377 212 Pages 4.8 (45)

Market Overview:

The global achondroplasia treatment market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in the market can be attributed to factors such as increasing prevalence of achondroplasia, rising awareness about available treatments, and technological advancements in the field of achondroplasia treatment. The global achondroplasia treatment market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into CNP analogue, ligand trap, TKI (tyrosine kinase inhibitor), and others. On the basis of application, the market is segmented into hospital-based care and retail pharmacy-based care. The regional segments are North America (U.S., Canada), Latin America (Mexico & Brazil), Europe (Germany & U.K.), Asia Pacific (China & Japan) and Middle East Africa).

Global Achondroplasia Treatment Industry Outlook

Product Definition:

Achondroplasia Treatment is the medical treatment used to improve the symptoms of achondroplasia. This treatment may include physical therapy, medications, and surgery.

CNP Analogue:

CNP Analogue is a drug that is developed to treat conditions associated with the cartilage and bone growth. CNP stands for Carteolide. It’s an anti-cancer drug used in chemotherapy protocols for patients with solid tumors, including breast cancer, Non-Small Cell Lung Cancer (NSCLC), and prostate cancer.

Ligand Trap:

Ligand trap is a new technique that has been used for the treatment of achondroplasia. It involves the use of an anti-LPS (Leukotriene Sulfate) drug to block the signaling pathway in Leukotrienes and Biphenol-A (BPA). The drug works by blocking two key enzymes involved in signal transduction, namely phospholipase A2 and platelet-derived growth factor receptor.

Application Insights:

The others segment held the largest share of more than 50.0% in the global achondroplasia treatment market in 2017. The other application includes bone grafts, autografts and allografts. These are used to treat post-operative complications and painful osteoarthritis that do not respond well to surgery or cannot be tolerated due to their adverse effects on other organs such as kidneys, lungs, heart etc.

Achondroplasia is most commonly treated with surgical procedures such as CNP analogues for pain management (intravenous), ligand trap for drug discovery & development (ligand-based therapy), thymidine kinase inhibitor (TKI) drugs for treating cancer & autoimmune diseases etc., among others which are under investigation phase at present time.

Regional Analysis:

North America dominated the global market in 2017. The presence of key players, favorable reimbursement policies, and increasing awareness levels are some of the factors responsible for its growth. For instance, in 2015, Actelion Pharmaceuticals Ltd., a subsidiary of Johnson & Johnson Services Inc., received approval from the U.S FDA to sell Dacogen (dactolisib) tablets for use against an AchR blocker drug in combination with hydroxyurea therapy for adults with active achondroplasia who have been treated by another method or whose disease progression is not responsive to treatment.

Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising disposable income coupled with improving healthcare infrastructure leading towards better diagnosis.

Growth Factors:

  • Increasing incidence of Achondroplasia
  • Growing awareness about Achondroplasia Treatment
  • Rising demand for minimally invasive treatments
  • Technological advancements in Achondroplasia Treatment
  • increasing healthcare expenditure

Scope Of The Report

Report Attributes

Report Details

Report Title

Achondroplasia Treatment Market Research Report

By Type

CNP Analogue, Ligand Trap, TKI, Others

By Application

Hospital, Retail Pharmacy, Others

By Companies

Ascendis Pharma, BioMarin, Ribomic, QED Therapeutics, Pfizer, Astellas

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year


Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year


Number of Pages


Number of Tables & Figures


Customization Available

Yes, the report can be customized as per your need.

Global Achondroplasia Treatment Market Report Segments:

The global Achondroplasia Treatment market is segmented on the basis of:


CNP Analogue, Ligand Trap, TKI, Others

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.


Hospital, Retail Pharmacy, Others

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. Ascendis Pharma
  2. BioMarin
  3. Ribomic
  4. QED Therapeutics
  5. Pfizer
  6. Astellas

Global Achondroplasia Treatment Market Overview

Highlights of The Achondroplasia Treatment Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. CNP Analogue
    2. Ligand Trap
    3. TKI
    4. Others
  1. By Application:

    1. Hospital
    2. Retail Pharmacy
    3. Others
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Achondroplasia Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global Achondroplasia Treatment Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available

Frequently Asked Questions?

Achondroplasia is a genetic disorder that affects the growth of the cartilage in the body. Treatment may include surgery to remove excess cartilage, physical therapy to help improve movement and breathing, and medications to reduce inflammation.

Some of the major players in the achondroplasia treatment market are Ascendis Pharma, BioMarin, Ribomic, QED Therapeutics, Pfizer, Astellas.

Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Achondroplasia Treatment Market Overview    4.1 Introduction       4.1.1 Market Taxonomy       4.1.2 Market Definition       4.1.3 Macro-Economic Factors Impacting the Market Growth    4.2 Achondroplasia Treatment Market Dynamics       4.2.1 Market Drivers       4.2.2 Market Restraints       4.2.3 Market Opportunity    4.3 Achondroplasia Treatment Market - Supply Chain Analysis       4.3.1 List of Key Suppliers       4.3.2 List of Key Distributors       4.3.3 List of Key Consumers    4.4 Key Forces Shaping the Achondroplasia Treatment Market       4.4.1 Bargaining Power of Suppliers       4.4.2 Bargaining Power of Buyers       4.4.3 Threat of Substitution       4.4.4 Threat of New Entrants       4.4.5 Competitive Rivalry    4.5 Global Achondroplasia Treatment Market Size & Forecast, 2020-2028       4.5.1 Achondroplasia Treatment Market Size and Y-o-Y Growth       4.5.2 Achondroplasia Treatment Market Absolute $ Opportunity

Chapter 5 Global  Market Analysis and Forecast by Type
   5.1 Introduction
      5.1.1 Key Market Trends & Growth Opportunities by Type
      5.1.2 Basis Point Share (BPS) Analysis by Type
      5.1.3 Absolute $ Opportunity Assessment by Type
   5.2  Market Size Forecast by Type
      5.2.1 CNP Analogue
      5.2.2 Ligand Trap
      5.2.3 TKI
      5.2.4 Others
   5.3 Market Attractiveness Analysis by Type

Chapter 6 Global  Market Analysis and Forecast by Applications
   6.1 Introduction
      6.1.1 Key Market Trends & Growth Opportunities by Applications
      6.1.2 Basis Point Share (BPS) Analysis by Applications
      6.1.3 Absolute $ Opportunity Assessment by Applications
   6.2  Market Size Forecast by Applications
      6.2.1 Hospital
      6.2.2 Retail Pharmacy
      6.2.3 Others
   6.3 Market Attractiveness Analysis by Applications

Chapter 7 Global Achondroplasia Treatment Market Analysis and Forecast by Region
   7.1 Introduction
      7.1.1 Key Market Trends & Growth Opportunities by Region
      7.1.2 Basis Point Share (BPS) Analysis by Region
      7.1.3 Absolute $ Opportunity Assessment by Region
   7.2 Achondroplasia Treatment Market Size Forecast by Region
      7.2.1 North America
      7.2.2 Europe
      7.2.3 Asia Pacific
      7.2.4 Latin America
      7.2.5 Middle East & Africa (MEA)
   7.3 Market Attractiveness Analysis by Region

Chapter 8 Coronavirus Disease (COVID-19) Impact 
   8.1 Introduction 
   8.2 Current & Future Impact Analysis 
   8.3 Economic Impact Analysis 
   8.4 Government Policies 
   8.5 Investment Scenario

Chapter 9 North America  Analysis and Forecast
   9.1 Introduction
   9.2 North America  Market Size Forecast by Country
      9.2.1 U.S.
      9.2.2 Canada
   9.3 Basis Point Share (BPS) Analysis by Country
   9.4 Absolute $ Opportunity Assessment by Country
   9.5 Market Attractiveness Analysis by Country
   9.6 North America  Market Size Forecast by Type
      9.6.1 CNP Analogue
      9.6.2 Ligand Trap
      9.6.3 TKI
      9.6.4 Others
   9.7 Basis Point Share (BPS) Analysis by Type 
   9.8 Absolute $ Opportunity Assessment by Type 
   9.9 Market Attractiveness Analysis by Type
   9.10 North America  Market Size Forecast by Applications
      9.10.1 Hospital
      9.10.2 Retail Pharmacy
      9.10.3 Others
   9.11 Basis Point Share (BPS) Analysis by Applications 
   9.12 Absolute $ Opportunity Assessment by Applications 
   9.13 Market Attractiveness Analysis by Applications

Chapter 10 Europe  Analysis and Forecast
   10.1 Introduction
   10.2 Europe  Market Size Forecast by Country
      10.2.1 Germany
      10.2.2 France
      10.2.3 Italy
      10.2.4 U.K.
      10.2.5 Spain
      10.2.6 Russia
      10.2.7 Rest of Europe
   10.3 Basis Point Share (BPS) Analysis by Country
   10.4 Absolute $ Opportunity Assessment by Country
   10.5 Market Attractiveness Analysis by Country
   10.6 Europe  Market Size Forecast by Type
      10.6.1 CNP Analogue
      10.6.2 Ligand Trap
      10.6.3 TKI
      10.6.4 Others
   10.7 Basis Point Share (BPS) Analysis by Type 
   10.8 Absolute $ Opportunity Assessment by Type 
   10.9 Market Attractiveness Analysis by Type
   10.10 Europe  Market Size Forecast by Applications
      10.10.1 Hospital
      10.10.2 Retail Pharmacy
      10.10.3 Others
   10.11 Basis Point Share (BPS) Analysis by Applications 
   10.12 Absolute $ Opportunity Assessment by Applications 
   10.13 Market Attractiveness Analysis by Applications

Chapter 11 Asia Pacific  Analysis and Forecast
   11.1 Introduction
   11.2 Asia Pacific  Market Size Forecast by Country
      11.2.1 China
      11.2.2 Japan
      11.2.3 South Korea
      11.2.4 India
      11.2.5 Australia
      11.2.6 South East Asia (SEA)
      11.2.7 Rest of Asia Pacific (APAC)
   11.3 Basis Point Share (BPS) Analysis by Country
   11.4 Absolute $ Opportunity Assessment by Country
   11.5 Market Attractiveness Analysis by Country
   11.6 Asia Pacific  Market Size Forecast by Type
      11.6.1 CNP Analogue
      11.6.2 Ligand Trap
      11.6.3 TKI
      11.6.4 Others
   11.7 Basis Point Share (BPS) Analysis by Type 
   11.8 Absolute $ Opportunity Assessment by Type 
   11.9 Market Attractiveness Analysis by Type
   11.10 Asia Pacific  Market Size Forecast by Applications
      11.10.1 Hospital
      11.10.2 Retail Pharmacy
      11.10.3 Others
   11.11 Basis Point Share (BPS) Analysis by Applications 
   11.12 Absolute $ Opportunity Assessment by Applications 
   11.13 Market Attractiveness Analysis by Applications

Chapter 12 Latin America  Analysis and Forecast
   12.1 Introduction
   12.2 Latin America  Market Size Forecast by Country
      12.2.1 Brazil
      12.2.2 Mexico
      12.2.3 Rest of Latin America (LATAM)
   12.3 Basis Point Share (BPS) Analysis by Country
   12.4 Absolute $ Opportunity Assessment by Country
   12.5 Market Attractiveness Analysis by Country
   12.6 Latin America  Market Size Forecast by Type
      12.6.1 CNP Analogue
      12.6.2 Ligand Trap
      12.6.3 TKI
      12.6.4 Others
   12.7 Basis Point Share (BPS) Analysis by Type 
   12.8 Absolute $ Opportunity Assessment by Type 
   12.9 Market Attractiveness Analysis by Type
   12.10 Latin America  Market Size Forecast by Applications
      12.10.1 Hospital
      12.10.2 Retail Pharmacy
      12.10.3 Others
   12.11 Basis Point Share (BPS) Analysis by Applications 
   12.12 Absolute $ Opportunity Assessment by Applications 
   12.13 Market Attractiveness Analysis by Applications

Chapter 13 Middle East & Africa (MEA)  Analysis and Forecast
   13.1 Introduction
   13.2 Middle East & Africa (MEA)  Market Size Forecast by Country
      13.2.1 Saudi Arabia
      13.2.2 South Africa
      13.2.3 UAE
      13.2.4 Rest of Middle East & Africa (MEA)
   13.3 Basis Point Share (BPS) Analysis by Country
   13.4 Absolute $ Opportunity Assessment by Country
   13.5 Market Attractiveness Analysis by Country
   13.6 Middle East & Africa (MEA)  Market Size Forecast by Type
      13.6.1 CNP Analogue
      13.6.2 Ligand Trap
      13.6.3 TKI
      13.6.4 Others
   13.7 Basis Point Share (BPS) Analysis by Type 
   13.8 Absolute $ Opportunity Assessment by Type 
   13.9 Market Attractiveness Analysis by Type
   13.10 Middle East & Africa (MEA)  Market Size Forecast by Applications
      13.10.1 Hospital
      13.10.2 Retail Pharmacy
      13.10.3 Others
   13.11 Basis Point Share (BPS) Analysis by Applications 
   13.12 Absolute $ Opportunity Assessment by Applications 
   13.13 Market Attractiveness Analysis by Applications

Chapter 14 Competition Landscape 
   14.1 Achondroplasia Treatment Market: Competitive Dashboard
   14.2 Global Achondroplasia Treatment Market: Market Share Analysis, 2019
   14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.3.1 Ascendis Pharma
      14.3.2 BioMarin
      14.3.3 Ribomic
      14.3.4 QED Therapeutics
      14.3.5 Pfizer
      14.3.6 Astellas

Our Trusted Clients

Contact Us